- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed releases lung agent in Europe
NeoSpect, a product for noninvasive diagnosis of suspected lung cancer, has entered the European market. The nuclear medicine product has been on the U.S. market since 1999 under the trade name NeoTect, which is being comarketed by Nycomed Amersham and
NeoSpect, a product for noninvasive diagnosis of suspected lung cancer, has entered the European market. The nuclear medicine product has been on the U.S. market since 1999 under the trade name NeoTect, which is being comarketed by Nycomed Amersham and Berlex. Developed and marketed by Nycomed Amersham Imaging, the agent binds selectively to the somatostatin receptor, which is overexpressed by malignant tumors in the lung. Current diagnostic methods typically uncover lung cancer only in advanced stages, offering little hope of recovery to the patient. NeoSpect has a high sensitivity for this type of cancer, raising prospects for early detection, according to the company. The high specificity may allow physicians to forego biopsy, otherwise required for a definitive diagnosis.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
